SAM
XENE icon

Shell Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Shell Asset Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-14,515
Closed -$559K – 1284
2023
Q2 		$559K Sell
14,515
-83
-0.6% -$3.3K 0.02% 535
2023
Q1 		$522K Sell
14,598
-51
-0.3% -$1.88K 0.02% 539
2022
Q4 		$578K Sell
14,649
-2,751
-16% -$100K 0.03% 484
2022
Q3 		$628K Sell
17,400
-4,625
-21% -$166K 0.02% 480
2022
Q2 		$670K Sell
22,025
-6
-0% -$181 0.02% 556
2022
Q1 		$673K Sell
22,031
-3,298
-13% -$98.7K 0.02% 659
2021
Q4 		$791K Buy
25,329
+164
+0.7% +$4.9K 0.02% 684
2021
Q3 		$385K Sell
25,165
-1,080
-4% -$18.8K 0.01% 979
2021
Q2 		$489K Buy
26,245
+1,440
+6% +$26.5K 0.01% 928
2021
Q1 		$444K Buy
+24,805
New +$420K 0.01% 903

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Shell Asset Management's XENE Position: Q3 2023 in Review

Shell Asset Management sold out of Xenon Pharmaceuticals (XENE) in Q3 2023, closing a stake of 14,515 shares — an estimated $559K sold.

Shell Asset Management first reported a position in XENE in Q1 2021 and held it in 10 quarters. The position peaked at $791K in Q4 2021. 180 funds tracked by Wall St. Rank hold XENE as of Q3 2023.

  • Shell Asset Management reported no remaining Xenon Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Shell Asset Management sold 14,515 Xenon Pharmaceuticals shares in Q3 2023, an estimated $559K.
  • Shell Asset Management first reported a position in Xenon Pharmaceuticals in Q1 2021 and held it in 10 quarters.
  • Shell Asset Management's Xenon Pharmaceuticals position peaked at $791K in Q4 2021.
  • 180 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2023.

Based on Shell Asset Management's 13F filing for Q3 2023, filed 8 Nov 2023.